Posted by Michael Wonder on 13 Feb 2017
Could UK’s post-Brexit regulator evaluate value as well?
9 February 2017 - GSK’s outgoing chief executive Sir Andrew Witty says the government must think carefully about post-Brexit drug regulation – but believes there are some creative possibilities.
In his final results conference as CEO of GSK yesterday, Witty said there are risks, but also benefits as the UK disentangles itself from the European regulatory framework.
Health secretary Jeremy Hunt last month said he expects the European Medicines Agency to move in a meeting with MPs.
Hunt added that the UK will leave the European regulatory system in order to ensure it’s not subject to decisions from the European Court of Justice after Brexit.
Witty told journalists in the conference call: “I assume that if the EMA moves it will create more disruption.”
